Evaluation of New Specifications (2.25mm) of FirehawkTM in the Treatment of Coronary Heart Disease ( Firehawk_2.25 )
The Safety and Effectiveness Evaluation of New Specifications (2.25mm) of FirehawkTM Sirolimus Target-eluting Coronary Stent System in the Treatment of Coronary Heart Disease: a Prospective, Multicenter, Single-group Study.
Sponsor: Shanghai MicroPort Medical (Group) Co., Ltd.
A NA clinical study on Coronary Heart Disease, this trial is completed. The trial is conducted by Shanghai MicroPort Medical (Group) Co., Ltd. and has accumulated 13 data snapshots since 2014. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Nov 2023 — Jul 2024 [monthly]
Completed NA
Status: Unknown Status → Completed
-
Jan 2023 — Nov 2023 [monthly]
Unknown Status NA
▶ Show 8 earlier versions
-
Dec 2022 — Jan 2023 [monthly]
Unknown Status NA
-
Jun 2022 — Dec 2022 [monthly]
Unknown Status NA
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Jun 2022 [monthly]
Active Not Recruiting NA
-
Aug 2020 — Jan 2021 [monthly]
Active Not Recruiting NA
-
Jun 2020 — Aug 2020 [monthly]
Active Not Recruiting NA
-
Mar 2020 — Jun 2020 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Mar 2020 [monthly]
Recruiting NA
-
Jan 2017 — Jun 2018 [monthly]
Recruiting NA
First recorded
May 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shanghai MicroPort Medical (Group) Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .